Last update 20 Mar 2025

Normal Human Immunoglobulin (KM Biologics KK)

Overview

Basic Info

Drug Type
Immunoglobulin
Synonyms
Freeze-Dried Sulfonated Normal Human Immunoglobulin, Kenketsu Venilon-I, Polyethylene glycoltreated human normalimmunoglobulin
+ [6]
Target-
Action
stimulants
Mechanism
Immunostimulants
Therapeutic Areas
Immune System DiseasesInfectious DiseasesNervous System Diseases+ [6]
Active Indication
Optic NeuritisMuscle WeaknessPolyradiculoneuropathy, Chronic Inflammatory Demyelinating+ [6]
Inactive Indication-
Originator Organization
Teijin Pharma Ltd.KM Biologics KKKM Biologics KK
Active Organization
KM Biologics KKKM Biologics KK
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Japan (22 May 1979),
AgammaglobulinemiaInfectious Diseases
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Normal Human Immunoglobulin (KM Biologics KK)
JPRN-jRCTs051220193
/ SuspendedNot ApplicableIIT
Single arm validation study of PEG-treated fully molecular human immunoglobulin (Venoglobulin IH) in patients with unexplained primaly recurrent pregnancy loss.
100 Clinical Results associated with Normal Human Immunoglobulin (KM Biologics KK)
Login to view more data
100 Translational Medicine associated with Normal Human Immunoglobulin (KM Biologics KK)
Login to view more data
100 Patents (Medical) associated with Normal Human Immunoglobulin (KM Biologics KK)
Login to view more data
2
Literatures (Medical) associated with Normal Human Immunoglobulin (KM Biologics KK)
01 Oct 2002Masui. The Japanese journal of anesthesiology
[Paravertebral block for labor analgesia in a parturient with idiopathic thrombocytopenia].
04 Mar 1962Vox SanguinisQ4 · MEDICINE
Intravenous Administration of Human γ‐Globulin*
Q4 · MEDICINE
100 Deals associated with Normal Human Immunoglobulin (KM Biologics KK)
Login to view more data

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Optic Neuritis
Japan
KM Biologics KKKM Biologics KK
20 Dec 2019
Muscle Weakness
Japan
KM Biologics KKKM Biologics KK
22 Aug 2019
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Japan
KM Biologics KKKM Biologics KK
22 Aug 2019
Granulomatosis With Polyangiitis
Japan
KM Biologics KKKM Biologics KK
20 Jan 2010
Guillain-Barre Syndrome
Japan
KM Biologics KKKM Biologics KK
12 Dec 2000
Mucocutaneous Lymph Node Syndrome
Japan
KM Biologics KKKM Biologics KK
28 Sep 1990
Purpura, Thrombocytopenic, Idiopathic
Japan
KM Biologics KKKM Biologics KK
16 Apr 1985
Agammaglobulinemia
Japan
KM Biologics KKKM Biologics KK
22 May 1979
Infectious Diseases
Japan
KM Biologics KKKM Biologics KK
22 May 1979
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free